Compare REED & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | REED | NSRX |
|---|---|---|
| Founded | 1987 | 2019 |
| Country | United States | Israel |
| Employees | 44 | 7 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.6M | 32.2M |
| IPO Year | N/A | N/A |
| Metric | REED | NSRX |
|---|---|---|
| Price | $1.73 | $3.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $19.67 |
| AVG Volume (30 Days) | 31.1K | ★ 52.6K |
| Earning Date | 05-12-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $18.74 | N/A |
| Revenue Next Year | $18.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.42 | $1.98 |
| 52 Week High | $5.97 | $9.99 |
| Indicator | REED | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 31.11 | 55.63 |
| Support Level | N/A | $2.04 |
| Resistance Level | $2.67 | $3.48 |
| Average True Range (ATR) | 0.35 | 0.25 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 17.21 | 68.83 |
Reed's Inc is a branded beverage company offering a portfolio of natural, premium, and functional beverages under the Reed's and Virgil's brands. The company's portfolio of handcrafted, all-natural beverages is sold in outlets nationwide, including the natural and specialty food channel, grocery stores, mass merchants, drug stores, convenience stores, club stores, and on-premise locations, including bars and restaurants. The company operates in a single reportable segment, which consists of manufacturing carbonated beverages under Reed's and Virgil's brand names.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.